Griffiths, RR; Richards, WA; McCann, U; Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 1 Aug 2006, 187 (3), 268–283. 342 kB. https://doi.org/10.1007/s00213-006-0457-5
Clarke, EGC. The identification of amphetamine type drugs. J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 31–36. 770 kB. https://doi.org/10.1016/S0015-7368(67)70368-0 #Methylphenidate TLC
McLaughlin, G; Morris, N; Kavanagh, PV; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Hessman, G; Murphy, B; Walther, D; Partilla, JS; Baumann, MH; Brandt, SD. Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo- and (±)-erythro- diastereomers. Drug Test. Anal., 1 Mar 2017, 9 (3), 347-357. 1.9 MB. https://doi.org/10.1002/dta.2167
Markowitz, JS; Zhu, H; Patrick, KS. Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. J. Child Adol. Psychop., 18 Dec 2013, 23 (10), 648–654. 328 kB. https://doi.org/10.1089/cap.2013.0074
Luethi, D; Kaeser, PJ; Brandt, SD; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology, 15 May 2018, 134 (A), 133-140. 987 kB. https://doi.org/10.1016/j.neuropharm.2017.08.020
Grafinger, KE; Hädener, M; König, S; Weinmann, W. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Test. Anal., 1 Mar 2018, 10 (3), 562-574. 1.2 MB. https://doi.org/10.1002/dta.2245
Barrett, FS; Griffiths, RR. Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 137-158. 848 kB. https://doi.org/10.1007/7854_2017_474
Montenarh, D; Hopf, M; Warth, S; Maurer, HH; Schmidt, P; Ewald, AH. A simple extraction and LC-MS/MS approach for the screening and identification of over 100 analytes in eight different matrices: Detection of 130 analytes in eight biosamples using only one LC-MS/MS method. Drug Test. Anal., 1 Mar 2015, 7 (3), 214-240. 593 kB. https://doi.org/10.1002/dta.1657
Calderon, SN; Klein, M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology, 1 Dec 2014, 87, 97-103. 266 kB. https://doi.org/10.1016/j.neuropharm.2014.04.001
Wilkins, C; Sweetsur, P. The impact of the prohibition of benzylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug Alcohol Depend., 1 Jan 2013, 127 (1-3), 72-80. 521 kB. https://doi.org/10.1016/j.drugalcdep.2012.06.014
Biel, JH; Bopp, BA. Amphetamines: Structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, 1 Jan 1978; pp 1–39. 1.0 MB. https://doi.org/10.1007/978-1-4757-0510-2_1
Broadley, KJ. The vascular effects of trace amines and amphetamines. Pharmacol. Ther., 1 Mar 2010, 125 (3), 363–375. 1.1 MB. https://doi.org/10.1016/j.pharmthera.2009.11.005 #methylphenidate
Nichols, DE. CNS Stimulants. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 89–120. 1.8 MB. https://doi.org/10.1002/0471266949.bmc243 #8
Hudkins, RL; Marino, MJ; Williams, M. Cognition. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 15–60. 784 kB. https://doi.org/10.1002/0471266949.bmc242 #9
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #128
Wenthur, CJ. Classics in Chemical Neuroscience: Methylphenidate. ACS Chem. Neurosci., 17 Aug 2016, 7 (8), 1030–1040. 531 kB. https://doi.org/10.1021/acschemneuro.6b00199 #1
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Piperidines Methylphenidate
Yadav-Samudrala, BJ; Eltit, JM; Glennon, RA. Synthetic cathinone analogs structurally related to the central stimulant methylphenidate as dopamine reuptake inhibitors. ACS Chem. Neurosci., 1 Aug 2019, 10 (9), 4043-4050. 1.1 MB. https://doi.org/10.1021/acschemneuro.9b00284 #1 NMR
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #PP-004, PP-005, PP-006
Carlier, J; Giorgetti, R; Varì, MR; Pirani, F; Ricci, G; Busardò, FP. Use of cognitive enhancers: methylphenidate and analogs. Eur. Rev. Med. Pharmacol. Sci., 1 Jan 2019, 23 (1), 3–15. 676 kB. https://doi.org/10.26355/eurrev_201901_16741 #MPH
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #I0 LC
Folen, VA. X-Ray powder diffraction data for some drugs, excipients, and adulterants in illicit samples. J. Forensic Sci., 1 Apr 1975, 20 (2), 348–372. 502 kB. https://doi.org/10.1520/JFS10282J #52 other
Takahashi, M; Suzuki, J; Nagashima, M; Seto, T; Yasuda, I. Analysis of anesthetics in uncontrolled drugs. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2005, 56 65–68. 975 kB. #RIT GC,LC,MS,NMR,IR,UV,TLC,other
Simmler, LD; Rickli, A; Schramm, Y; Hoener, MC; Liechti, ME. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem. Pharmacol., 15 Mar 2014, 88 (2), 237–244. 504 kB. https://doi.org/10.1016/j.bcp.2014.01.024 #Methylphenidate
Angenoorth, TJF; Stankovic, S; Niello, M; Holy, M; Brandt, SD; Sitte, HH; Maier, J. Interaction profiles of central nervous system active drugs at human organic cation transporters 1–3 and human plasma membrane monoamine transporter. Int. J. Mol. Sci., 30 Nov 2021, 22 (23), 12995. 5.1 MB. https://doi.org/10.3390/ijms222312995 #Methylphenidate